Navigation Links
Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
Date:5/4/2008

disease. Phase 1, 2 and 3 study data have been reported showing that motavizumab appears to have a similar safety and pharmacokinetic profile to Synagis(R) (palivizumab) in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract. In its pivotal clinical trial, which was a head-to-head comparative trial with Synagis, motavizumab demonstrated non-inferiority with a 26-percent relative reduction in RSV hospitalizations due to RSV, which was its primary endpoint, and a 50- percent relative reduction in the incidence of RSV lower respiratory tract infections requiring outpatient management, one of its secondary endpoints. Rates of adverse events, serious adverse events and study drug discontinuations were balanced between treatment groups.

About Synagis

Synagis (palivizumab) is indicated for the prevention of serious lung infections caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Synagis is given as a shot, usually in the thigh muscle, each month during the RSV season. The first dose of Synagis should be given before RSV season begins. Children who develop an RSV infection while receiving Synagis should continue the monthly dosing schedule throughout the season. Synagis has been used in more than one million children in the U.S. since its introduction in 1998.

Synagis is not currently recommended as a preventive measure among Native American infants at high risk for serious RSV disease.

Very rare cases (<1 per 100,000 patients) of severe allergic reactions such as anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. These rare reactions may occur when any dose of Synagis is given, not just the first one. Also, rare but serious side effects can occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Other side effects with Synag
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... and MOUNTAIN VIEW, Calif. , July ... leader in translational preclinical research, today unveiled their new ... signaling the transformation of Surpass, corporate culture to one ... our customers. This press release comes on the heels ... were added to the Silicon Valley Team:  David Craig, ...
(Date:7/23/2014)... 23, 2014 On Tuesday, July 1, ... suit in the 116 th Judicial District ... against RegenLab USA, LLC ("Defendant") for ... Relationships through false and misleading actions, fraud, ... Disparagement through libel, disparagement, defamation, misrepresentation, and ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- Use of Risk ... programs to delay generic market entry results in $5.4 ... new survey and analysis by economic consulting firm ... - http://photos.prnewswire.com/prnh/20140723/129680 Required by the ... and biologics, REMS programs are intended to improve drug ...
Breaking Medicine Technology:SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2
... Inc ., a clinical-stage epigenetics oncology company, announced today ... with entinostat in combination and as a single agent ... San Antonio Breast Cancer Symposium ... phase 2 study of exemestane with and without entinostat ...
... MALVERN, Pa., Dec. 1, 2011 Auxilium Pharmaceuticals, Inc. ... today announced that the first patient has been dosed ... (collagenase clostridium histolyticum) for the treatment of idiopathic ... Shoulder syndrome. (Logo:  http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
Cached Medicine Technology:Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 2Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 3Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 4Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 5Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 2Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 3Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 4Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 5Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 6
(Date:7/23/2014)... of research suggesting a safe and effective role ... cancer, with fewer detrimental side effects and improved ... study will be published in final format today ... Endocrinology . , Breast cancer is the most ... States. Approximately 70% of breast cancers are diagnosed ...
(Date:7/23/2014)... July 23, 2014 Rich Dad® Education, a ... of their charity yard sale to support Habit for Humanity ... 100% of the proceeds will be donated to Habitat for ... are being donated to the Habitat for Humanity ReStore thrift ... 33903. , One of the highlights of the yard ...
(Date:7/23/2014)... York (PRWEB) July 23, 2014 Thousands ... to move forward in a federal multidistrict litigation underway ... Liebhard LLP reports. According to an Order dated July ... hospital’s bid for payment of a $1,000 fee for ... implant. , Among other things, the Order noted ...
(Date:7/23/2014)... better treating the pernicious disorders of obesity and dementia ... American University,s Center for Behavioral Neuroscience. In the paper, ... aimed at areas of the brain responsible for memory ... could play a role in reducing certain dementias., "In ... measures often fall short. This is a new way ...
(Date:7/23/2014)... Olympic gold medal-winning speed skater Chad ... Friday, July 18. Hedrick visited Roanoke as the special ... an Olympic-style event celebrating its 25th Anniversary in 2014. ... premier sponsor of the Commonwealth Games, which like Foot ... and all activity levels. , Hedrick, a native of ...
Breaking Medicine News(10 mins):Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 4Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:US Olympian Chad Hedrick Visits Foot Levelers 2
... , ... Care of Serious Illness is the first book to provide a comprehensive look at the ... E. Meier, Stephen L. Isaacs, Robert Hughes (Editors) , ... New York, NY (Vocus) April 1, 2010 -- Palliative Care: Transforming ...
... they know how cytomegalovirus continues to re-infect people , THURSDAY, ... how a virus known as cytomegalovirus (CMV), which infects up ... re-infects people again and again even though their immune systems ... always make people ill, but certain people, such as newborns ...
... SNM and the Radiological Society of North America (RSNA) ... at the Natcher Conference Center of the National Institutes ... workshop will focus on general issues of standardization to ... and analysis of images in clinical trials. The second ...
... beat vitamin B for those with scent-robbing viral infection, ... Acupuncture may help people who lose their sense of ... a new study, 15 patients with post-viral olfactory dysfunction ... acupuncture. These patients were compared with PVOD patients treated ...
... new study of brain activity in depressed and anxious people ... modified for better or for worse by anxiety. ... Behavioral Neuroscience , looked at depression and two types of ... panic; and anxious apprehension, better known as worry. The ...
... ... Mac platforms , ... Richardson, TX (PRWEB) April 1, 2010 -- Damaka, a technology pioneer in Mobile ... Real-time 2-way Video, Application Sharing) Sweeping™ between laptops and mobile devices earlier in May ...
Cached Medicine News:Health News:Palliative Care: Transforming the Care of Serious Illness 2Health News:Palliative Care: Transforming the Care of Serious Illness 3Health News:Demystifying a Common, Persistent Virus 2Health News:FDA, SNM and RSNA host April 13-14 two-topic imaging workshop 2Health News:Depressed? Fearful? It might help to worry, too 2Health News:Damaka Delivers Advanced Sweeping&#8482; Capability of Live Sessions Across Multiple Devices Over WiFi, 3G and 4G Networks 2
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
... The Shuttle Relay Suture Passer allows braided ... tissue repair procedures. It may be ... suture material and in conjunction with anchors ... anchor) Additionally, the Shuttle Relay can ...
... EMR Electronic Medical Record organizes communication ... and with outside practitioners. It also ... and other data that traditionally rely ... the patient chart. With Microsoft Outlook ...
Medicine Products: